louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03855566: Telenutrition Center: Examining the Implementation of Behavioral Therapy for Obesity
Official title: Telenutrition Center: Examining the Implementation of Behavioral Therapy for Obesity Among Young to Middle Aged African American Adults in Mississippi
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Obesity
Lead sponsor: University of Southern Mississippi
Sponsor class: OTHER
Collaborators: name: My Brother's Keeper
First posted: 2019-02-26
Enrollment: 38
Sex: ALL
Minimum age (years): 25
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The Telenutrition Center will use the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) Framework to assess the implementation of an evidence-based, intensive behavior therapy (IBT) for obesity intervention (with a motivational interviewing \[MI\] framework) based on the Centers for Medicaid and Medicare Services (CMS) IBT for obesity benefit. The intervention will be examined under real-world conditions with technology supplementation to address obesity and related chronic disease among young adult (18-50 years of age) African Americans across the state. The intervention contact will model the CMS IBT for obesity benefit according to the patient contact schedule (of weekly visits in the first month, biweekly in months 2-7, and once a month per months 8-12) and include nutrition, stage of change and other physical and psychosocial assessments. Program delivery will be assisted by the "Bridge2U" web and mobile platform and supported in both clinic and community settings. The proposed project will shed new light on how IBT for obesity (and similar) models may be amended to facilitate the provision of health care resources in areas with limited to no resources, such as the state of Mississippi.


Eligibility criteria: Inclusion Criteria:

* Body mass index \>/=28
* 25 to 50 years of age
* history or risk of preventable co-morbidities (ie. diabetes, hypertension, and/or dyslipidemia)

Exclusion Criteria:

* Body mass index \<28
* \<25 years of age
* \>50 years of age
* no history or risk of preventable obesity comorbidities
* Any disease diagnosis (ie. cancer) where weight loss is contraindicated

Primary outcomes:
measure: Weight Changes
timeFrame: 0, 6 and 12 months
measure: Retention
timeFrame: 12 months
Secondary outcomes:
Other outcomes:
Locations:
city: Hattiesburg
country: United States
facility: The University of Southern Mississippi
state: Mississippi
Study officials:
References:
Clinical trial NCT03206866: Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma
Official title: Role of Serum Regucalcin in Diagnosis of Hepatocellular Carcinoma
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Role of Serum Regucalcin in Diagnosis of HCC
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2017-07-02
Enrollment: 96
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients will be subjected to the following:

* Detailed History taking.
* Physical examination.
* Routine laboratory investigations essential for diagnosis and follow up of patients including:

  1. Complete blood count (CBC).
  2. Chemistry profile: serum bilirubin-serum albumin-SGPT-SGOT.
  3. serum regucalcin(SMP30) antibodies using ELISA
  4. AFP level.
* Radiological assessment:

US, Triphasic CT to assess (tumor site, size, numbers, nodal metastases, distal metastases, portal vein invasion..)

Brief summary: Although the diagnosis and therapy of HCC have being improved, the poor prognosis still remains. To reduce the mortality and improve the effectiveness of diagnosis and therapy, it is important to detect the protein biomarkers which are associated with HCC tumor progression and may be useful as potential diagnosis or therapeutic targets.

SMP30 (senescence marker protein 30)(serum regucalcin), which we have previously identiﬁed from Guangxi HCC cDNA expression library by the SEREX approach, is one of the hepatocellular carcinoma associated antigens \[4\]

Serum antibody response to SMP30 in various patients using the methods of Western-blot and ELISA and showed that antibody to SMP30 existed mainly in HCC patients (39.8%), especially in the one with alpha-fetoprotein (AFP) negative


Eligibility criteria: Inclusion Criteria:

1. Newly diagnosed cases of HCC (be based on NCCN guidelines triphasic CT and AFP or liver biopsy)
2. Adult patients
3. Both genders are eligible.
4. Informed consent obtained from subject or subject's legal representative

Exclusion Criteria:

1. Patient with other malignancies.
2. Patients with advanced comorbidities except for renal failure.
3. Prior chemotherapy

Primary outcomes:
measure: serum regucalcin in HCC patients
timeFrame: 1-12-2016 to 1-12-2017
Secondary outcomes:
Other outcomes:
Locations:
city: Mansoura
country: Egypt
facility: Oncology Center Mansoura University
state: Dakahlia
Study officials:
References:
Clinical trial NCT03776266: The Long-term Clinical Outcomes and Patterns of Transfusion in PCI Patients: Retrospective Cohort Study
Official title: The Five-year Pattern of Red Blood Cell Transfusion and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: A Korean Nationwide Longitudinal Cohort Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Erythrocyte Transfusion
Percutaneous Coronary Intervention
Revascularization
Keywords: Transfusion
PCI
Percutaneous Coronary Intervention
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2018-12-14
Enrollment: 48786
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients undergoing PCI using stent in 2011 from all medical providers in Korea is selected using National Healthcare Insurance System

Brief summary: A nationwide retrospective cohort study. To investigate the long-term patterns of transfusion and clinical outcomes of patients undergoing PCI.

Detailed description: A nationwide retrospective cohort study. Transfusion after PCI may increase a risk, but the long term effects after red blood cell transfusion is known. Longitudinal data is collected from administrative claims in the National Healthcare Insurance Service of Korea. All Korean patient date undergoing PCI inserting stent from January 1, 2011 to December 31, 2011 is extracted. Clinical outcomes until December 31, 2016 is investigated.

Primary outcome is the incidence density of red blood cell transfusion. Secondary outcomes are the association of transfusion with major adverse clinical event (MACE) consisting all-cause death, revascularization, critically ill cardiovascular status, or stroke.

Incidence density and time-dependent Cox proportional hazard regression is statistically analyzed.

Eligibility criteria: Inclusion Criteria:

* All Korean patients undergoing PCI using stent from January 1, 2011 to December 31, 2011

Exclusion Criteria:

* Patients without any stent insertion

Primary outcomes:
measure: Incidence density of transfusion
timeFrame: 5 years
Secondary outcomes:
measure: Incidence density of MACE
timeFrame: 5 years
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
state: Gang nam-Gu, Ilwon-Dong
Study officials:
affiliation: Samsung Medical Center
name: Jin-Ho Choi, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00770666: Combination Medications vs. Patch Alone for Medically-Ill Smokers
Official title: Flexibly-Dosed Combination Pharmacotherapy Versus Standard-Dosed Nicotine Patch Alone for Smokers With Medical Illness
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Smoking Cessation
Keywords: Tobacco dependence treatment
Lead sponsor: Rutgers, The State University of New Jersey
Sponsor class: OTHER
Collaborators: name: Rutgers Cancer Institute of New Jersey
name: Robert Wood Johnson Foundation
First posted: 2008-10-10
Enrollment: 127
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Randomized clinical trial to evaluate a flexibly-dosed-3-medication combination for up to 6 months in smokers with medical illness

Detailed description: Subjects randomly received either nicotine patch alone for a 10-week, tapering course (n=64) or the combination of nicotine patch, nicotine oral inhaler, and bupropion for an ad-lib duration (n=63).

Eligibility criteria: Inclusion Criteria:

* currently smoking at least 10 cigarettes per day (confirmed by high exhaled carbon-monoxide (CO))
* 18 years or older
* interested in quitting within the next 30 days
* one or more pre-defined medical illnesses (including cardiovascular disease, other vascular disease, chronic pulmonary disease, cancer, hypertension, diabetes, hyperlipidemia, and recurrent pulmonary infections)

Exclusion Criteria:

* contraindications to pharmacotherapy (including unstable angina, myocardial infarction within 2 months, severe arrhythmia, seizure disorder, serious mental illness requiring antipsychotic medications)
* current use of other tobacco products (smokeless tobacco, cigars, pipes, etc.), bupropion, clonidine, nortriptyline, or nicotine replacement medications
* unable to give consent

Primary outcomes:
measure: Tobacco use abstinence
timeFrame: 26 week
Secondary outcomes:
measure: Time to first relapse
timeFrame: varies
measure: Duration of medication use
timeFrame: 26 weeks
measure: Adverse clinical events
timeFrame: 26 weeks
Other outcomes:
Locations:
city: New Brunswick
country: United States
facility: Umdnj-Rwjms
state: New Jersey
Study officials:
affiliation: UMDNJ-RWJMS
name: Michael B Steinberg, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, Carson JL. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med. 2009 Apr 7;150(7):447-54. doi: 10.7326/0003-4819-150-7-200904070-00004.
Clinical trial NCT06493266: The Effect of Neurolingualistik Programming (NLP) on Pain Score, Fear of Pain and Pain Catastrophizing Before Colposcopy
Official title: The Effect of Neurolingualistik Programming (NLP) on Pain Score, Fear of Pain and Pain Catastrophizing Before Colposcopy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pain, Acute
Keywords: pain
NLP
colposcopy
Lead sponsor: Sanliurfa Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2024-07-09
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Colposcopy, evaluation of cervical cytological abnormalities and It is the gold standard procedure for the early diagnosis of preinvasive and invasive diseases. Despite her Essentially a minimally invasive intervention, even referring the patient to colposcopy can cause significant anxiety and distress in patients. Increased anxiety can also lead to deterioration in health-related quality. Studies have been conducted to reduce the anxiety of women undergoing colposcopy, but there are no publications on topics such as anxiety, pain perception, and pain catastrophizing.

Neuro Linguistic Programming (NLP) has been called "the art and science of personal excellence", "the study of subjective experience". NLP helps us understand the difference between our actions that produce mediocre results or failure and those that require success or excellence.

NLP: "How do I do something I do well?", "How can I do it better?", "How can I gain skills that I admire in others? It addresses questions like ". It is important to note that NLP is not limited to observable behavior. Our way of thinking, that is, all experience and It also includes the mental processes that control our actions. By dealing with the entire structure of a person's experience (in fact, their motivation), it tries to shape the thought processes, emotions and beliefs that result in a behavior. It is especially about our communication with ourselves as well as with others.

No study was planned on pain and pain perception during colposcopy by teaching the NLP technique to the patients.


Eligibility criteria: Inclusion Criteria:Those who are over 18 years of age and are not pregnant with an indication for colposcopy; Those who agreed to participate in the study,

Exclusion Criteria:patients who understand and can speak Turkish patients who did not meet the inclusion criteria or had previously undergone colposcopy - -

Primary outcomes:
measure: pain evaluation
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Sanliurfa
country: Turkey
facility: Sanliurfa Education and Research Hospital
city: Şanlıurfa
country: Turkey
facility: Sanliurfa Education and Research Hospital
Study officials:
affiliation: Sanliurfa Education and Research Hospital
name: aysegül kılıçlı
role: STUDY_CHAIR
References:
Clinical trial NCT05612126: Pre- and Post-tests Impact of a Football Tournament on the Mental Well-being of Kuru Community Youths in Jos-South: A Single Arm Mixed Methods Study
Official title: Pre- and Post-tests Impact of a Football Tournament on the Mental Well-being of Kuru Community Youths in Jos-South: A Single Arm Mixed Methods Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Football Tournament
Lead sponsor: Nottingham Trent University
Sponsor class: OTHER
Collaborators: name: Teesside University
name: Coal City University
name: Dung Jidong Foundation
First posted: 2022-11-10
Enrollment: 200
Sex: MALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Kuru community male youths in Jos-South local government area of Plateau State Nigeria.

Brief summary: Sporting activities such as football tournaments are instrumental in promoting community mental health. A community-based football tournament intervention will benefit the participating individuals' physical and mental health and promote community cohesion.

The anticipated benefits of the proposed football tournament are:

* To bring a greater sense of community cohesion and togetherness.
* To improve physical and mental health (e.g., increase fitness, reduce anxiety, depression, loneliness, suicidal ideation or self-harm).


Eligibility criteria: Inclusion Criteria:

* Male youths
* Between 18 and 35 years
* Able to give informed consent
* Residents of the Kuru community of Jos-South
* No history of chronic health concerns (e.g., chronic heart disease, severe depression etc).

Exclusion Criteria:

* Females
* Below 18 or above 35 years
* Unable to give informed consent
* History of chronic health concerns (e.g., chronic heart disease, severe depression etc).

Primary outcomes:
measure: Change in Football Worry is being assessed
timeFrame: Change is being assessed at pre and post-intervention at 8 weeks
measure: Change in Moral Disengagement in Sport is being assessed
timeFrame: Change is being assessed at pre and post-intervention at 8 weeks
measure: Change in Positive Mental Health is being assessed
timeFrame: Change is being assessed at pre and post-intervention at 8 weeks
measure: Change in Psychological Well-Being is being assessed
timeFrame: Change is being assessed at pre and post-intervention at 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03816826: "THE EFFECTS OF LOW LEVEL LASER THERAPY VERSUS STRAIN/COUNTER STRAIN TECHNIQUE IN ACUTE SOFT TISSUE INJURIES"
Official title: "THE EFFECTS OF LOW LEVEL LASER THERAPY VERSUS STRAIN/COUNTER STRAIN TECHNIQUE IN ACUTE SOFT TISSUE INJURIES"
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Hamstring Injury
Strain Counter Strain
Lead sponsor: Isra University
Sponsor class: OTHER
First posted: 2019-01-25
Enrollment: 60
Sex: ALL
Minimum age (years): 16
Maximum age (years): 32
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: 60 athletes with hamstring injury distributed randomly into 3 group
Primary purpose: TREATMENT

Brief summary: Muscle strain injuries are common in sports but are often misdiagnosed and maltreated.

Their significance is often underestimated because most athletes can continue their daily activities soon after the injury. Proximal hamstrings strains have attracted greater attention because they have a high incidence which is approximately 42%.

Detailed description: it will be randomized control trial with 60 patients with Acute hamstring Injuries divided into 3 groups. One group will be given Laser therapy, 2nd will be given Strain/Counter Strain technique and 3rd will be given both the techniques in combination This study will be conducted in Rehabilitation setup of Pakistan Hockey Federation Lahore, and Institute of Orthopedics and Rehabilitation Center Garden Town Lahore. Non probability Convenience Sampling technique will be utilized

Eligibility criteria: Inclusion Criteria:

hamstring injury patient with grade 2 or 1 both male and female local tenderness on palpation pain with resisted knee flexion pain with resisted hip extension pain on stretching of effected area

Exclusion Criteria:

* patient with fracture
* patient with grade 3 orthopedic condition like ankylosing spondylitis medically unstable

Primary outcomes:
measure: visual analogue scale
timeFrame: 5 days
measure: FASH questionaire
timeFrame: 5 days
Secondary outcomes:
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Dr Adnan
state: Punjab
Study officials:
References:
Clinical trial NCT04693026: Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
Official title: Efficacy of Ramdicivir and Baricitinib Combination Therapy for the Treatment of COVID 19 ARDS
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Covid19
Covid-19 ARDS
Keywords: COVID 19
Covid-19 ARDS
Tocilizumab
Remdicivir
Baricitinib
Lead sponsor: M Abdur Rahim Medical College and Hospital
Sponsor class: OTHER_GOV
Collaborators: name: First affiliated Hospital Xi'an Jiaoting University
First posted: 2021-01-05
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to compare the outcome of the "Remdesivir + Baricitinib" combination against "Remdesivir + Tocilizumab" therapy and find the best option for the management of ARDS in COVID-19 patients.


Eligibility criteria: Inclusion Criteria:

Severe COVID-19 patients require hospitalization under HDU/ICU. The SARSCoV-2 infection will be confirmed by RT PCR / CT Chest in every case.

Exclusion Criteria:

Participants with uncontrolled clinical status who were hospitalized from the before. Contraindication / possible drug interaction. Participants who have any severe and/or uncontrolled medical conditions like, Severe ischemic heart disease, epilepsy, malignancy, Pulmonary/ renal/hepatic disease, AIDS, Pulmonary TB, pregnancy, Corpulmonale, and etc.

Primary outcomes:
measure: Time to Clinical Improvement (TTCI)
timeFrame: Following randomization 30 days
Secondary outcomes:
measure: Mortality Rate
timeFrame: Following randomization 30 days.
measure: Duration of ICU stay
timeFrame: Following randomization 30 days.
measure: Duration total hospital stay
timeFrame: Following randomization 30 days.
measure: Rate of daily Supplemental Oxygen Use
timeFrame: Following randomization 30 days.
measure: Time to Clinical Failure
timeFrame: Following randomization 30 days.
Other outcomes:
Locations:
city: Dinajpur
country: Bangladesh
facility: M. Abdur Rahim Medical College Hospital
Study officials:
affiliation: First Affiliated Hospital Xi'an Jiaotong University
name: Abu Taiub Mohammed Mohiuddin Chowdhury, MBBS, MD
role: STUDY_CHAIR
affiliation: M Abdur Rahim Medical College and Hospital
name: Akter Kamal, MD, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04444726: Phototherpy Versus Tapwater Iontophoresis for Management of Atopic Dermatitis in Children.
Official title: Phototherpy Versus Tap Water Iontophoresis for Management of Atopic Dermatitis in Children, Randomized Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atopic Dermatitis
Keywords: Atopic dermatitis, Phototherapy, iontophoresis
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2020-06-23
Enrollment: 60
Sex: ALL
Minimum age (years): 9
Maximum age (years): 16
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: this study is conducted to compare the effect of phototherapy" psoralen plus UVA " bath puva to tap water iontophoresis in the treatment of atopic dermatitis in children.

Detailed description: Sixty children were selected from the department of dermatology, Banha University Hospital. Patients were randomly assigned to (Group- A):- 20 children Patients, aged between 6-16 years old. be treated with Phototherapy, for 3 sessions per week for 8 weeks Plus the traditional medical treatment. which is the betamethasone dipropionate 0.05% " diprolene for 2 times a day for 8 weeks. (Group B): 20 children Patients, in Group-B are treated with tap water iontophoresis, for 8 weeks, 3 sessions /week: the intensity were increased according to the patient's tolerance, for 20 minutes. Plus the traditional medical treatment. (Group -C) the control group will treated by only the traditional medical treatment which is the betamethasone dipropionate 0.05% " diprolene" cream, two times a day for 8 weeks Skin thickness by ultrasonography and Patient Oriented Eczema Measure(POEM) are measured before and after 8 weeks of treatment.

Eligibility criteria: Inclusion Criteria:

* Age between 9 to 16 years.
* Suffering from AD of dyshidrotic as well as dry types of more than 6-months duration
* Traditional types of treatment options, including oral or topical corticosteroids, proved ineffective.

Exclusion Criteria:

* Intolerance history to UV radiation.
* Skin malignancy at the area to be treated.
* Acute infection at the treated area.
* Children received radiotherapy in the area to be treated during the last 6 months.
* Children received corticosteroid therapy topically within 14 days before treatment, or systemic corticosteroids or any immunosuppressive drugs within the last 4 weeks.
* Circulatory and sensory disorders and children with diabetes mellitus.

Primary outcomes:
measure: Patient Oriented Eczema Measure" POEM"
timeFrame: 8 weeks of treatment
Secondary outcomes:
measure: Thickness of the skin " Ultrasonography"
timeFrame: 8 weeks of treatment
Other outcomes:
Locations:
city: Banhā
country: Egypt
facility: Banha University
Study officials:
References: